Clinical Trials
All Clinical Trials - Page 7 of 52
A complete, crawlable index of every tracked clinical trial of peptide compounds. Use the search browser at /trials for filtering, or page through the full list here.
- NCT06967389N/ARecruiting
Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity
Semaglutide
- NCT06931028Phase 3Recruiting
A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2
Mazdutide
- NCT06989177N/ARecruiting
Probiotic Intervention on Body Weight
Semaglutide
- NCT06989203N/ARecruiting
Protein Supplementation Intervention on Body Weight
Semaglutide
- NCT07015268Phase 3Active Not Recruiting
A Clinical Study of KLH-2109 in Patients With Endometriosis
Gonadorelin
- NCT06982846Phase 1Completed
A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia
Retatrutide
- NCT07011667Phase 3Active Not Recruiting
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
Semaglutide
- NCT06982859Phase 1Recruiting
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
Retatrutide
- NCT07293325N/ARecruiting
Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity
Tirzepatide
- NCT06639464Phase 2Recruiting
Semaglutide for Helping Opioid Recovery
Semaglutide
- NCT07610174Phase 2Completed
Effects of Dapagliflozin, Semaglutide, and Their Combination in Heart Failure Patients With Prosthetic Heart Valves
Semaglutide
- NCT07035093Phase 3Recruiting
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
Retatrutide
- NCT06851962Phase 4Active Not Recruiting
Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.
Semaglutide
- NCT06901349Phase 2Withdrawn
A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes
Tirzepatide
- NCT07094568N/ARecruiting
Tirzepatide vs Liraglutide in Bone
Tirzepatide
- NCT05974774Phase 3Recruiting
Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors
Gonadorelin
- NCT06742710Phase 4Recruiting
Liraglutide Treatment in Obese Infertile PCOS Women
Liraglutide
- NCT06972472Phase 3Active Not Recruiting
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
Orforglipron
- NCT06972459Phase 3Active Not Recruiting
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
Orforglipron
- NCT06993792Phase 3Active Not Recruiting
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
Orforglipron
- NCT06976853Phase 2Recruiting
Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease
Tirzepatide
- NCT06962280Phase 3Active Not Recruiting
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight
Tirzepatide
- NCT06937203Phase 1/Phase 2Recruiting
A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus
Tirzepatide
- NCT06884293Phase 3Active Not Recruiting
A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）
Semaglutide
- NCT07029009Phase 2Recruiting
Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)
Liraglutide
- NCT06939088Phase 2Recruiting
Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder
Tirzepatide
- NCT06965413Phase 2Active Not Recruiting
A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity
Tirzepatide
- NCT07057310Phase 4Enrolling By Invitation
Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women
Tirzepatide
- NCT06901245Phase 4Recruiting
Tirzepatide in PWS, HO and GNSO
Tirzepatide
- NCT07055607N/AEnrolling By Invitation
A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice
Semaglutide
- NCT06865365Phase 4Not Yet Recruiting
Preoperative Use of Liraglutide Additionally to Common Dietological Measures as Opposed to Dietological Measures Alone
Liraglutide
- NCT07109700Phase 2Recruiting
A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin
Dulaglutide
- NCT06948435Phase 3Active Not Recruiting
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
Orforglipron
- NCT06948422Phase 3Active Not Recruiting
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
Orforglipron
- NCT06952530Phase 3Active Not Recruiting
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
Orforglipron
- NCT06914895Phase 3Active Not Recruiting
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
Tirzepatide
- NCT06972992Phase 1Completed
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide
Semaglutide
- NCT06706284Phase 4Recruiting
Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes
Semaglutide
- NCT06916065Phase 1Completed
A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity
Tirzepatide
- NCT06802081Phase 2Recruiting
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
Tirzepatide
- NCT06911203Phase 2Recruiting
A Study of BGM0504 in Participants With Obesity
Tirzepatide
- NCT06983171N/AActive Not Recruiting
Semaglutide Effectiveness in Patients With Metabolic Dysfunction-Associated Fatty Liver Disease in the Real World Practice
Semaglutide
- NCT06619015Phase 2/Phase 3Withdrawn
Tailoring Obesity Treatment Trial
Semaglutide
- NCT06966687N/AEnrolling By Invitation
Protective Effect of Ulinastatin and Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA XI)
Thymosin-Alpha-1
- NCT06862908Phase 2Recruiting
A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity
Mazdutide
- NCT06894784Phase 3Recruiting
A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes
Semaglutide
- NCT07244003Phase 4Recruiting
Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control
Liraglutide
- NCT06897475Phase 2Recruiting
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
Tirzepatide
- NCT06721507Phase 4Recruiting
2024 Tirzepatide-Bariatric Surgery
Tirzepatide
- NCT06745284Phase 1Active Not Recruiting
A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity
Semaglutide